8U5 Stock Overview
Engages in the production and sale of biochemicals in Australia, France, the United Kingdom, Belgium, and Norway.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
Circa Group AS Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | NOK 0.067 |
| 52 Week High | NOK 0.41 |
| 52 Week Low | NOK 0.055 |
| Beta | -0.025 |
| 11 Month Change | -5.87% |
| 3 Month Change | -29.35% |
| 1 Year Change | -78.60% |
| 33 Year Change | -95.55% |
| 5 Year Change | n/a |
| Change since IPO | -95.80% |
Recent News & Updates
Recent updates
Shareholder Returns
| 8U5 | DE Chemicals | DE Market | |
|---|---|---|---|
| 7D | -12.2% | 0.1% | 0.9% |
| 1Y | -78.6% | 3.9% | 5.7% |
Return vs Industry: 8U5 underperformed the German Chemicals industry which returned 3.9% over the past year.
Return vs Market: 8U5 underperformed the German Market which returned 5.7% over the past year.
Price Volatility
| 8U5 volatility | |
|---|---|
| 8U5 Average Weekly Movement | 24.0% |
| Chemicals Industry Average Movement | 4.0% |
| Market Average Movement | 4.7% |
| 10% most volatile stocks in DE Market | 10.1% |
| 10% least volatile stocks in DE Market | 2.5% |
Stable Share Price: 8U5's share price has been volatile over the past 3 months.
Volatility Over Time: 8U5's weekly volatility has increased from 15% to 24% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2006 | 17 | Bertel Karlstedt | www.circa-group.com |
Circa Group AS engages in the production and sale of biochemicals in Australia, France, the United Kingdom, Belgium, and Norway. The company extracts value from non-food waste biomass to produce bio-based chemicals through its Furacell production process. Its products include Cyrene, a polar aprotic solvent; and Levoglucosenone derivatives.
Circa Group AS Fundamentals Summary
| 8U5 fundamental statistics | |
|---|---|
| Market cap | €11.51m |
| Earnings (TTM) | -€6.32m |
| Revenue (TTM) | €1.65m |
7.0x
P/S Ratio-1.8x
P/E RatioIs 8U5 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 8U5 income statement (TTM) | |
|---|---|
| Revenue | €1.65m |
| Cost of Revenue | €488.00k |
| Gross Profit | €1.16m |
| Other Expenses | €7.48m |
| Earnings | -€6.32m |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
Aug 22, 2024
| Earnings per share (EPS) | -0.052 |
| Gross Margin | 70.37% |
| Net Profit Margin | -383.49% |
| Debt/Equity Ratio | 0% |
How did 8U5 perform over the long term?
See historical performance and comparison